Theravance Biopharma (TBPH) Peer Comparison
$17.08
$0.00 (0.00%)As on 04-Sep-2026 16:00EDT
Market cap
$887 Mln
Revenue (TTM)
$104 Mln
P/E Ratio
16.4
P/B Ratio
3.1
Div. Yield
0 %
| Theravance Biopharma (TBPH) | Aptorum Group Limited Class A - ADR | |
|---|---|---|
Market cap ($ Mln) |
887 | 1 |
Revenue ($ Mln) |
104 | 1 |
Net Profit ($ Mln) |
53.81 | -5.68 |
Net Margin (%) |
51.58 | -591.67 |
RoE (%) |
18.35 | -49.04 |
Price to Earnings |
16.42 | -- |
Price-To-Book |
3.06 | 0.28 |
Cashflow ($ Mln)
| Theravance Biopharma (TBPH) | Aptorum Group Limited Class A - ADR | |
|---|---|---|
|
Cash From Operating Activities
|
238.54 | -1.84 |
|
Cash Flow from Investing Activities
|
-105.28 | -- |
|
Cash from Financing Activities
|
-3.25 | 4.41 |
|
Net Cash Inflow / Outflow
|
-- | -- |
Ratios
Profitability Ratios
| Theravance Biopharma (TBPH) | Aptorum Group Limited Class A - ADR | |
|---|---|---|
|
ROCE (%)
|
35.44 | -5.34 |
|
ROE (%)
|
18.35 | -49.04 |
|
ROA (%)
|
10.97 | -59.31 |
|
EBIT Margin (%)
|
61.61 | 0.00 |
|
Net Margin (%)
|
51.58 | -591.67 |
|
Cash Profit Margin (%)
|
0.00 | -- |
Growth Ratios
| Theravance Biopharma (TBPH) | Aptorum Group Limited Class A - ADR | |
|---|---|---|
|
Revenue Growth (%)
|
35.11 | -- |
|
EBIT Growth (%)
|
50.13 | -- |
|
Net Profit Growth (%)
|
312.92 | 68.06 |
|
EPS Growth (%)
|
331.49 | 0.98 |
|
Book Value Growth (%)
|
26.50 | -- |
Valuation Ratios
| Theravance Biopharma (TBPH) | Aptorum Group Limited Class A - ADR | |
|---|---|---|
|
Price / Earnings
|
9.37 | -5.72 |
|
Price / Book Value
|
3.06 | 0.34 |
|
Dividend Yield (%)
|
0.00 | -- |
|
EV/EBITDA
|
9.45 | -4.28 |
|
Market Cap ($ Cr)
|
-- | -- |
Solvency Ratios
| Theravance Biopharma (TBPH) | Aptorum Group Limited Class A - ADR | |
|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.04 | 74.65 |
|
Current Ratio
|
13.54 | 0.45 |
|
Quick Ratio
|
13.54 | 0.45 |
|
Interest Coverage
|
51.97 | -35.64 |
Operating Efficiency Ratios
| Theravance Biopharma (TBPH) | Aptorum Group Limited Class A - ADR | |
|---|---|---|
|
Debtors to sales (%)
|
19.54 | 0.00 |
|
Asset Turnover
|
0.21 | 0.10 |
|
Receivable days
|
278.67 | -- |
|
Inventory Days
|
-4,537.51 | -- |
|
Payable days
|
159.28 | -- |
|
Cash Conversion Cycle
|
-4,418.12 | -- |